Surufatinib plus Sintilimab and IBI310 in patients with high-grade advanced-neuroendocrine neoplasm (HG-NEN): A multicenter, single arm phase 2 study

#3933

Introduction: Surufatinib (SUR, a selective VEGFRs, FGFR1 and CSF-1R inhibitor). Preclinical and clinical studies have shown that SUR is the best partner of immune checkpoint inhibitors (ICI).

Aim(s): To evaluate the efficacy and safety of SUR combined with Sintilimab (SIN, anti-PD-1) and IBI310 (IBI, anti-CTLA-4) in advanced grade-3 neuroendocrine tumor (G3 NET) and neuroendocrine carcinoma (NEC) patients (pts).

Materials and methods: Eligible HG-NEN pts were those who failed, could not tolerate, were not suitable or unwilling to receive standard treatment. Enrolled pts received SUR (250mg, qd, po, q3w) combined with SIN (200mg, d1, i.v.gtt, q3w) and IBI (1mg/kg, d1, i.v.gtt, q6w). The primary endpoint was ORR per RECIST 1.1.

Conference:

Presenting Author: Zhang P

Authors: Zhang P, Wang Y, Li J, Shen L, Lu M,

Keywords: Surufatinib, Sintilimab, IBI310, high-grade advanced-neuroendocrine neoplasm,